CTRI/2021/11/038303Completed未知
Olanzapine for control of Cisplatin-induced emesis: A prospective randomised study
Dr P Rama0 sites60 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients receiving Cisplatin will be recruited.
Exclusion Criteria
- •1. Patients who deviate from the already designed protocol
- •2. Pregnant and lactating women
- •3. Psychiatric patients
- •4. Patients with arrythmia
- •5. Patients with renal impairment (Creatinine clearance: <15ml/min/1.73m 2 )
- •6. Patients treated with Amitriptyline
- •7. Patients experiencing nausea/ vomiting due to mechanical obstruction
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Aprepitant in the prevention of cisplatin-induced delayed emesis: a double-blind randomized study - Aprepitant for cisplatin-induced delayed emesisEUCTR2008-001339-37-ITAZIENDA OSPEDALIERA S. MARIA DI TERNI560
Completed
Not Applicable
Comparison of 2 interventions for preventing vomiting after short surgeries post discharge from hospitalCTRI/2021/12/038684PGIMER106
Completed
Phase 3
â??Utility of olanzapine for prevention of nausea and vomiting in children and young adults receiving cancer chemotherapy.CTRI/2017/07/009092AIIMS240
Recruiting
Phase 3
Olanzapine augmentation therapy in treatment-resistent depression: a double-blind placebo-controlled trialF32F33Depressive episodeRecurrent depressive disorderDRKS00000021niversitätsklinikum Freiburg60
Completed
Not Applicable
Orlistat therapy in clozapine- and olanzapine-treated patients who are overweight or obeseNutritional, Metabolic, EndocrineObesityISRCTN65731856The Stanley Medical Research Institute (SMRI) (USA)80